Home|Prescribing Information|Contact Us|Site Map
Types of GnRH Therapies

There are 3 types of GnRH agonist therapy:

  • Daily or monthly injection: Although injection therapy may be given as frequently as once a day, the most common regimen is once a month. The injection must be given on a regular monthly schedule; otherwise, your child will restart puberty. Such tight scheduling can be inconvenient, which may cause problems for you and your child.
  • Multiple-times-daily nasal spray: This therapy must be administered either twice or 3 times a day. Each dose consists of 2 or 3 sprays per nostril, for a total of 8 to 9 sprays each day.
  • Once-yearly implant: A novel way to get GnRH agonist medicine is from a small implant, called SUPPRELIN® LA, which lasts for a full year.

Your child’s doctor should do tests to make sure your child has CPP before treating with a GnRH agonist. Only you and your doctor can determine the best treatment option for your child with CPP.

Register with SUPPRELIN LA

Indication

SUPPRELIN® LA (histrelin acetate) implant is used for the treatment of children with central precocious puberty (CPP).

Important Safety Information

SUPPRELIN LA should not be used by women who are or may become pregnant, and in patients who are allergic to gonadotropin releasing hormone (GnRH) or GnRH agonist analogs. Safety and effectiveness in children under 2 years of age has not been determined.

SUPPRELIN LA, like other GnRH agonists, may cause a temporary increase in the blood levels of specific hormones associated with the onset of puberty (estrogen in girls and testosterone in both sexes) during the first week of treatment. This increase may temporarily worsen puberty symptoms during the first week, additionally, you may see new symptoms appear during this period. Within the 4 weeks of treatment with SUPPRELIN LA, hormonal suppression generally occurs and the physical signs of puberty should decrease.

Your doctor should monitor the levels of specific hormones associated with puberty progression, 1 month after starting SUPPRELIN LA and then every 6 months thereafter. Every 6-12 months, height and bone age should be also monitored by your doctor.

During the clinical trial testing of SUPPRELIN LA, the most common side effects involved the implant site and included temporary bruising, pain, soreness, redness of the skin and swelling.

Please talk with your doctor for more information or if you have any questions.

Endo Pharmaceuticals
Rx Only
© 2010 Endo Pharmaceuticals. All rights reserved.
SUPPRELIN® LA is a registered trademark of Endo Pharmaceuticals.
SP-1007/June 2009

Privacy/Legal
Intended for U.S. Residents Only